PL4009978T3 - Stosowanie sepiapteryny i jej metabolitów w leczeniu narażenia na promieniowanie - Google Patents
Stosowanie sepiapteryny i jej metabolitów w leczeniu narażenia na promieniowanieInfo
- Publication number
- PL4009978T3 PL4009978T3 PL20758407.9T PL20758407T PL4009978T3 PL 4009978 T3 PL4009978 T3 PL 4009978T3 PL 20758407 T PL20758407 T PL 20758407T PL 4009978 T3 PL4009978 T3 PL 4009978T3
- Authority
- PL
- Poland
- Prior art keywords
- sepiapterin
- metabolites
- radiation exposure
- treat radiation
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882937P | 2019-08-05 | 2019-08-05 | |
| PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4009978T3 true PL4009978T3 (pl) | 2025-02-24 |
Family
ID=72148243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20758407.9T PL4009978T3 (pl) | 2019-08-05 | 2020-08-05 | Stosowanie sepiapteryny i jej metabolitów w leczeniu narażenia na promieniowanie |
Country Status (21)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7778477B2 (ja) | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| US12691119B2 (en) | 2021-02-09 | 2026-07-28 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| WO2005048926A2 (en) * | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| PT3138566T (pt) | 2003-11-17 | 2022-02-02 | Biomarin Pharm Inc | Tratamento de fenilcetonúria com bh4 |
| CA2545968C (en) | 2003-11-17 | 2010-03-09 | Merck Eprova Ag | Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| US20100130500A1 (en) | 2004-12-08 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| KR20160065998A (ko) | 2007-04-11 | 2016-06-09 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| WO2010017570A2 (de) | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| JP5066756B2 (ja) | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| CA2828685C (en) | 2011-03-01 | 2018-05-29 | Rubicon Research Private Limited | Stable compositions of tetrahydrobiopterin |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| JP6084967B2 (ja) | 2012-05-07 | 2017-02-22 | 白鳥製薬株式会社 | セピアプテリン及びテトラヒドロラクトイルプテリンの製造法 |
| JP2016530333A (ja) * | 2013-09-13 | 2016-09-29 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用 |
| CN114306208A (zh) * | 2014-10-02 | 2022-04-12 | 西托索尔本茨公司 | 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途 |
| WO2018019931A1 (en) | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| WO2018102315A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymoprhs of sepiapterin and salts thereof |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| JP7778477B2 (ja) | 2018-05-30 | 2025-12-02 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| CA3102105A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Compositions and methods for increasing tetrahydrobiopterin plasma exposure |
| JP7502197B2 (ja) | 2018-05-30 | 2024-06-18 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリン血漿曝露を増加させるための方法 |
| LT4009978T (lt) * | 2019-08-05 | 2024-11-25 | Ptc Therapeutics Mp, Inc. | Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui |
| CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| US12691119B2 (en) | 2021-02-09 | 2026-07-28 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| AR127191A1 (es) | 2021-09-29 | 2023-12-27 | Ptc Therapeutics Inc | Composición farmacéutica de sepiapterina |
-
2020
- 2020-08-05 LT LTEPPCT/US2020/045026T patent/LT4009978T/lt unknown
- 2020-08-05 SM SM20250089T patent/SMT202500089T1/it unknown
- 2020-08-05 US US17/631,995 patent/US12667569B2/en active Active
- 2020-08-05 SI SI202030521T patent/SI4009978T1/sl unknown
- 2020-08-05 JP JP2022507561A patent/JP7642611B2/ja active Active
- 2020-08-05 PL PL20758407.9T patent/PL4009978T3/pl unknown
- 2020-08-05 PT PT207584079T patent/PT4009978T/pt unknown
- 2020-08-05 EP EP24187395.9A patent/EP4454712A3/en active Pending
- 2020-08-05 CN CN202411691224.1A patent/CN119837879A/zh active Pending
- 2020-08-05 ES ES20758407T patent/ES2994060T3/es active Active
- 2020-08-05 CN CN202080069308.5A patent/CN114555090B/zh active Active
- 2020-08-05 EP EP20758407.9A patent/EP4009978B1/en active Active
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en not_active Ceased
- 2020-08-05 AU AU2020324435A patent/AU2020324435B2/en active Active
- 2020-08-05 HR HRP20241653TT patent/HRP20241653T1/hr unknown
- 2020-08-05 RS RS20241189A patent/RS66096B1/sr unknown
- 2020-08-05 DK DK20758407.9T patent/DK4009978T3/da active
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 FI FIEP20758407.9T patent/FI4009978T3/fi active
- 2020-08-05 HU HUE20758407A patent/HUE069012T2/hu unknown
-
2022
- 2022-02-03 IL IL290321A patent/IL290321B2/en unknown
-
2025
- 2025-02-26 JP JP2025029508A patent/JP2025098011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4009978A1 (en) | 2022-06-15 |
| EP4454712A2 (en) | 2024-10-30 |
| SMT202500089T1 (it) | 2025-03-12 |
| ES2994060T3 (en) | 2025-01-16 |
| CA3146477A1 (en) | 2021-02-11 |
| IL290321B2 (en) | 2026-08-01 |
| US12667569B2 (en) | 2026-06-30 |
| US20220273661A1 (en) | 2022-09-01 |
| EP4454712A3 (en) | 2025-01-01 |
| CN114555090A (zh) | 2022-05-27 |
| IL290321A (en) | 2022-04-01 |
| PT4009978T (pt) | 2024-11-05 |
| HRP20241653T1 (hr) | 2025-04-25 |
| JP7642611B2 (ja) | 2025-03-10 |
| AU2020324435B2 (en) | 2026-03-19 |
| LT4009978T (lt) | 2024-11-25 |
| RS66096B1 (sr) | 2024-11-29 |
| JP2022543655A (ja) | 2022-10-13 |
| BR112022002029A2 (pt) | 2022-06-07 |
| FI4009978T3 (fi) | 2024-11-01 |
| IL290321B1 (en) | 2026-04-01 |
| CN119837879A (zh) | 2025-04-18 |
| EP4009978B1 (en) | 2024-09-25 |
| MX2022001535A (es) | 2022-03-04 |
| AU2020324435A1 (en) | 2022-02-24 |
| HUE069012T2 (hu) | 2025-02-28 |
| CN114555090B (zh) | 2024-12-17 |
| SI4009978T1 (sl) | 2025-03-31 |
| WO2021026247A1 (en) | 2021-02-11 |
| JP2025098011A (ja) | 2025-07-01 |
| DK4009978T3 (da) | 2024-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290321B1 (en) | Use of spiapterin and its metabolites for radiation exposure treatment | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| IL278978A (en) | Preparations and methods for treating eczema | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL280000A (en) | Formulations for reducing tumors and methods of using them | |
| GB2589398B (en) | Compounds and methods of use | |
| EP3692973A4 (en) | BACK SUPPORT FOR ANKLE SPHAT, AND ANKLE SPHAT | |
| EP3749700B8 (de) | Mit aktinischer strahlung fixierbare masse und ihre verwendung | |
| IL283061A (en) | Use of dantrolene and dantrolene prodrugs to treat radiation exposure | |
| IL274433A (en) | Fulvestrant formulations and methods of using them | |
| GB2562661B (en) | Oil palm phenolics composition for the protection of human organs, cells and tissues against the injurious effects of exposure to ionizing radiation | |
| IL272847B1 (en) | Methods of using dantrolene to treat nerve gas exposure | |
| SG11202009795PA (en) | Protection of biologically active molecules during radiation sterilization | |
| ZA202100752B (en) | Treatment and prevention of injury due to radiation exposure | |
| HK40060691A (en) | Use of dantrolene and dantrolene prodrugs to treat radiation exposure | |
| IL282566A (en) | Synthesis of (s)-6-hydroxytryptophan and derivatives thereof | |
| IL272018A (en) | Device for testing radiation doses and method of operation | |
| IL278575B1 (en) | Dantrolene formulations and methods of using them | |
| SG11202106692UA (en) | Deuterated forms and derivatives of volinanserin | |
| GB201908573D0 (en) | Compounds and methods of use | |
| IL283912A (en) | Methods for treating cancer using the platenoside molecule and its isomers | |
| IL277988A (en) | Compounds and methods for treating demyelination | |
| HK40051014A (en) | Methods and compositions for treating chronic effects of radiation and chemical exposure | |
| HK40042340A (en) | Using power loss density and related measures to quantify the dose of tumor treating fields (ttfields) | |
| GB201815000D0 (en) | Treatment of hypothroidism and related conditions |